Nasdaq3d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...
Nasdaq7d
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global ...
Nasdaq4d
Is Vertex (VERX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Vertex (VERX) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but also carries a top Zacks Rank. Research shows that stocks ...
Nasdaq4d
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
Vertex Pharmaceuticals (VRTX ... Elsewhere, the Dow gained 0.91%, while the tech-heavy Nasdaq added 1.35%. The the stock of drugmaker has fallen by 12.22% in the past month, lagging the Medical ...
Nasdaq11d
Check Out What Whales Are Doing With VRTX
Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the trades showed up on ...
Nasdaq9d
Vertex price target lowered to $535 from $600 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $535 from $600 and keeps a Buy rating on the shares after the company announced results ...
Nasdaq12d
Why Vertex Pharmaceuticals (VRTX) Outpaced the Stock Market Today
Vertex Pharmaceuticals (VRTX ... Meanwhile, the Dow experienced a drop of 0.25%, and the technology-dominated Nasdaq saw an increase of 1.24%. The drugmaker's shares have seen a decrease of ...
Nasdaq5d
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people with cystic fibrosis (CF) aged six years and above. The drug will be ...
Nasdaq8d
Vertex's Cystic Fibrosis Drug Alyftrek Gets FDA Approval
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Nasdaq6d
Vertex Pharmaceuticals price target lowered to $500 from $503 at JPMorgan
JPMorgan lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $500 from $503 and keeps an Overweight rating on the shares. Alyftrek’s approval with a higher U.S. price than ...
Nasdaq10d
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
– Treatment with the highly selective NaV1.8 pain signal inhibitor suzetrigine met the primary endpoint with a statistically significant and clinically meaningful 2.02 point within-group ...
Nasdaq13d
Vertex, Inc. Recognized as Leader in Multiple IDC MarketScape Reports for Tax Technology Solutions
Vertex, Inc. has been named a Leader in three IDC MarketScape reports for tax automation software, highlighting its industry expertise and growth. Vertex, Inc., a leading provider of tax ...